Kirin (KNBWY)
(Delayed Data from OTC)
$14.16 USD
+0.69 (5.14%)
Updated Aug 8, 2025 03:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Kirin Holdings Co. has a PEG ratio of 2.27 compared to the Beverages - Alcohol industry's PEG ratio of 1.83.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KNBWY 14.16 +0.69(5.14%)
Will KNBWY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KNBWY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KNBWY
KNBWY vs. BUD: Which Stock Is the Better Value Option?
Are Investors Undervaluing Kirin (KNBWY) Right Now?
KNBWY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bear of the Day: Constellation Brands (STZ)
KNBWY or BUD: Which Is the Better Value Stock Right Now?
Is Kirin (KNBWY) Stock Undervalued Right Now?
Other News for KNBWY
Kirin Holdings: Q1 Performance Had Mixed Takeaways
Kirin Holdings: Promising Health Science Growth Amidst Pharmaceutical Challenges, Hold Rating Maintained
Kirin Holdings: Hold Rating Amid Disappointing Q1 Results and Margin Challenges